New Therapeutic Strategies for Lewy Body Dementias

@article{Velayudhan2017NewTS,
  title={New Therapeutic Strategies for Lewy Body Dementias},
  author={L. Velayudhan and D. Ffytche and C. Ballard and D. Aarsland},
  journal={Current Neurology and Neuroscience Reports},
  year={2017},
  volume={17},
  pages={1-9}
}
This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available symptom treatment strategies are based on monoaminergic, cholinergic and glutaminergic neurotransmitter systems. Relatively robust evidence exists for cholinesterase inhibitors for cognitive impairment in LBD and in Parkinson’s disease for antidepressants, clozapine and recently pimavanserin for psychosis. interpidine (RVT 101) and nelotanserin are currently under… Expand
Advances in the pharmacotherapeutic management of dementia with Lewy bodies
TLDR
An overview of the current pharmacotherapy in DLB is provided and potential new drugs are in ongoing clinical trials and it is likely that novel drug targets for the development of better and more effective symptomatic products and disease-modifying therapies are identified. Expand
Pharmacological Management of Dementia with Lewy Bodies
TLDR
The three cholinesterase inhibitors that have been shown to be effective in managing the cognitive and behavioral symptoms of DLB: rivastigmine, galantamine and donepezil are discussed. Expand
Clinical drug development for dementia with Lewy bodies: past and present
TLDR
An overview of the DLB drug development landscape and the current treatment strategies is provided and new biomarker strategies are necessary to improve diagnostic capabilities and trial designs, and novel drug targets should be identified to develop DLB specific disease-modifying therapies. Expand
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials
TLDR
There are opportunities to improve the landscape of LBD clinical trials by harmonizing clinical assessments and biomarkers across cohorts and research studies, developing and validating outcome measures in LBD, engaging the patient community to assess research needs and priorities, and incorporating biomarker and genotype profiling in study design. Expand
Parkinson's Disease Dementia and Lewy Body Disease.
TLDR
Although the diagnosis is basically clinical, structural and functional neuroimaging as well as cerebrospinal fluid biomarkers may help the clinician in the diagnosis. Expand
Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies
TLDR
An individual with DLB with severe distressing persistent visual hallucinations and agitation was reported, and clozapine was successfully initiated with substantial improvement in both clinical and functional outcomes. Expand
[Dementia with Lewy bodies].
TLDR
Dementia with Lewy bodies is characterized histopathologically by the deposition of α-synuclein in inclusion bodies and therapy concepts include treatment of loss of motor and cognitive performance as well as psychological and behavioral symptoms. Expand
Recent updates in the Alzheimer's disease etiopathology and possible treatment approaches: a narrative review of current clinical trials.
TLDR
The presences of a small number of candidates in the last phase suggest that a large number of candidate have had an undesirable side effect or were unable to pass essential eligibility for future phases of AD. Expand
Lewy Body Dementia: A Review
TLDR
Lewy Body Dementia is a frequent and complex neurodegenerative pathology, shorter in duration than Alzheimer’s disease, although there are few double-blind clinical studies on drug therapies, the place of anticholinesterase inhibitors, L-dopa and new antipsychotics is slowly emerging. Expand
The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies
TLDR
It is shown that Montelukast might be a promising drug candidate for future DLB therapy development and presenting leukotriene signaling as a potential drug target for DLB and reducing the protein aggregation load in neurodegenerative diseases. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 72 REFERENCES
Combination therapies: The next logical Step for the treatment of synucleinopathies?
  • E. Valera, E. Masliah
  • Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2016
TLDR
The current evidence supporting this type of approach is reviewed, suggesting that such rational therapy combinations, together with the use of multi‐target drugs, may hold promise as the next logical step for the treatment of synucleinopathies. Expand
Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
TLDR
Cholinesterase inhibitors appear beneficial for the treatment of Lewy body disorders without detrimental effects on motor function, however, a careful monitoring of treatment compliance and side effects is required. Expand
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis
  • Huifu Wang, J. Yu, +6 authors L. Tan
  • Psychology, Medicine
  • Journal of Neurology, Neurosurgery & Psychiatry
  • 2014
TLDR
Cholinesterase inhibitors and memantine slightly improve global impression; however, only cholines terase inhibitors enhance cognitive function. Expand
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
TLDR
Patients with DLB or PDD might benefit from treatment with memantine, which was well tolerated, and large-scale studies are now required to confirm the preliminary findings. Expand
Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
TLDR
Preliminary evidence suggests that transgenic mice treated with an antibody directed against α-synuclein oligomers/protofibrils resulted in reduced levels of such species in the CNS, and immunotherapy targeting α- Synuclein holds promise, but needs to be further developed as a future disease-modifying treatment in Parkinson's disease and other α- synucleinopathies. Expand
Diagnosis and management of dementia with Lewy bodies
TLDR
The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. Expand
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
TLDR
Pimavanserin was well tolerated with no significant safety concerns or worsening of motor function and may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist. Expand
Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
TLDR
High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare and strategies for important areas of need, such as autonomic symptoms and caregiver burden, have not been investigated. Expand
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
TLDR
Results to date suggest that immunotherapy is a promising therapeutic approach for neurodegenerative diseases that progress with the accumulation and prion-like propagation of toxic protein aggregates. Expand
Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
TLDR
Early treatment with memantine and a positive clinical response to memantine predicted longer survival in patients with DLB and PDD, suggesting a possible disease-modifying effect and also has implications for health economic analysis. Expand
...
1
2
3
4
5
...